Most cases of ALS are not directly inherited in the way many people assume, but genetics plays a larger role than the traditional picture suggests. Roughly 5 to 10 percent of people with ALS have a clear family history of the disease or a related condition like frontotemporal dementia, and in about 80 percent of those familial cases a specific gene variant can be identified. The remaining 90-plus percent of cases are classified as “sporadic,” meaning no obvious family pattern exists. Yet even in sporadic ALS, genetic susceptibility contributes meaningfully, with overall heritability estimates ranging from about 40 to 60 percent. The line between “inherited” and “not inherited” turns out to be far blurrier than the textbook categories imply.
How Often ALS Runs in Families
A large meta-analysis pooling data from 165 studies found that the overall proportion of familial ALS was about 8 percent, though the number shifted depending on how studies were designed. Population-based studies, which tend to capture a broader and less biased cross-section of patients, put the figure closer to 5 percent. Case series from specialized clinics, where patients with unusual or severe presentations tend to concentrate, reported rates around 9 percent.1PubMed Central. Estimated Familial Amyotrophic Lateral Sclerosis Proportion: A Literature Review and Meta-Analysis The standard answer you will encounter in clinical settings is that 5 to 10 percent of ALS cases are familial and the rest are sporadic. That framing is useful but incomplete, because the word “sporadic” does not mean “no genetic involvement.” It just means no one else in the family had ALS that anyone knew about.
The Major Genes Involved
More than 40 genes have been linked to ALS susceptibility so far, but four account for the lion’s share of identified familial cases: C9orf72, SOD1, TARDBP, and FUS.2PubMed Central. The genetics of amyotrophic lateral sclerosis Each of these genes damages motor neurons through a different mechanism, and the clinical picture varies depending on which one is mutated.
The C9orf72 repeat expansion is the single most common genetic cause of ALS in people of Northern European descent. It also causes frontotemporal dementia, and in some families, both diseases show up across generations. The mutation involves a short stretch of DNA that gets repeated far more times than normal, and three broad mechanisms of harm have been proposed: the cell loses the normal function of the C9orf72 protein, the abnormal RNA transcripts build up and trap other essential proteins, and unusual toxic proteins get manufactured from the expanded repeats through an unconventional process.3PubMed Central. C9orf72-mediated ALS and FTD: multiple pathways to disease4PubMed Central. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS Researchers believe a combination of all three is probably at work, which helps explain why the disease is so aggressive.
SOD1 mutations were the first ALS gene mutations identified, back in the early 1990s, and they remain one of the better-understood causes. The SOD1 protein normally protects cells from oxidative damage, but mutations cause it to misfold and clump together. These misfolded proteins accumulate on the surface of mitochondria in spinal-cord motor neurons, which seems to be a tissue-specific vulnerability.5PubMed Central. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria Oxidative stress can worsen the problem, pushing the misfolded protein into forms of aggregation that resemble what is seen in ALS tissue.6PubMed. Early steps in oxidation-induced SOD1 misfolding: implications for non-amyloid protein aggregation in familial ALS
TARDBP mutations are rarer, accounting for roughly 3 to 5 percent of familial cases and under 1 percent of sporadic ones. But the protein it encodes, TDP-43, turned out to be extraordinarily important: abnormal TDP-43 deposits are the hallmark pathology in the vast majority of all ALS cases, even those without any TARDBP mutation.7PubMed Central. Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy8PubMed Central. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis In other words, even when the gene itself is not mutated, the protein it produces goes wrong in most people with ALS. That discovery transformed how researchers think about the disease.
FUS mutations tend to show up in younger patients. The FUS protein normally works inside the cell nucleus, but mutations, especially those affecting its nuclear-import signal, cause it to leak out and accumulate in the cytoplasm of motor neurons.9Human Molecular Genetics. Pathology of three ALS patients with FUS variants, including one likely benign Q23L variant lacking FUS inclusions In studies comparing fast and slow disease progression, FUS mutations appeared exclusively in the fast-progressing group.10PubMed. Fast versus slow disease progression in amyotrophic lateral sclerosis-clinical and genetic factors at the edges of the survival spectrum
Why “Sporadic” ALS Is Not Purely Random
The clean division between familial and sporadic ALS breaks down under closer examination. Known gene mutations account for about 70 percent of familial cases but also turn up in roughly 15 percent of sporadic ones.11Nature. The amyotrophic lateral sclerosis exposome: recent advances and future directions That means a substantial number of people with no family history of ALS are still carrying pathogenic gene variants. Several things can explain this. Some mutations have low penetrance, meaning you can carry the variant and never develop symptoms, so the disease can skip generations and appear to come out of nowhere. Others arise fresh in the affected person as de novo mutations, brand-new errors not inherited from either parent.
Researchers have confirmed that de novo mutations in SOD1 can cause sporadic ALS. In one study, four sporadic patients were found to have new SOD1 mutations that had not been present in their parents’ DNA. Their symptoms matched those of familial cases carrying the same mutations.12PubMed Central. De novo mutations in SOD1 are a cause of ALS Another study sequenced the genomes of 47 sporadic ALS patients alongside both their unaffected parents and found an enrichment of new amino-acid-altering mutations in genes involved in chromatin regulation.13PubMed Central. Exome sequencing to identify de novo mutations in sporadic ALS trios De novo events help explain why a disease with a strong genetic component can still appear to arise spontaneously.
Beyond single high-impact gene mutations, common genetic variants with individually small effects also contribute to ALS risk. Heritability estimates for ALS fall between 40 and 60 percent, which means that genetics accounts for a large chunk of who develops the disease, even in the absence of a single identifiable culprit gene.14PubMed. Recent advances in the genetics of familial and sporadic ALS Factors that influence how genes are expressed, like aging, also play a role. A person can carry a pathogenic variant for decades before the combination of genetic susceptibility, age, and environmental exposures pushes them past a threshold. One influential model suggests ALS onset requires multiple “hits,” at least some of which could be environmental, even when a highly penetrant mutation is present.15Nature. The amyotrophic lateral sclerosis exposome: recent advances and future directions
How Specific Mutations Shape the Course of Disease
Not all ALS-causing mutations are equal. The specific variant you carry can dramatically influence when symptoms begin and how fast the disease progresses. Among SOD1 mutations alone, there is wide variation. One particularly aggressive variant is associated with a mean disease duration of about one year, while another variant in the same gene averages around five years.16PubMed. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase A large analysis of many SOD1 variants found considerable variation in both age of onset and survival, with an interesting twist: some variants were associated with younger onset but longer survival than typical ALS, meaning onset and duration do not always move in the same direction.17Nature Communications. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration
Gene identity also matters for progression speed. In one study comparing the fastest and slowest progressing ALS patients, C9orf72 expansions and FUS mutations appeared only in the fast-progression group, while SOD1 variants were well represented in both fast and slow groups, making up three-quarters of all monogenic cases among slow progressors.18PubMed. Fast versus slow disease progression in amyotrophic lateral sclerosis-clinical and genetic factors at the edges of the survival spectrum Carrying more than one rare variant can worsen things further. In one Chinese family, a member with three variants in different ALS genes had a much more severe disease course than a relative who carried only one of the three.19PubMed Central. Presence of Rare Variants is Associated with Poorer Survival in Chinese Patients with Amyotrophic Lateral Sclerosis
ALS Genetics Vary by Population
Which genes drive ALS depends heavily on ancestry and geography. The C9orf72 repeat expansion dominates in populations of Northern European descent but is rare in many Asian populations. The reverse is true for SOD1 mutations, which are more common in familial ALS among Asian populations but relatively infrequent in sporadic cases in European-descended groups.20PubMed Central. Heterogeneity of frequencies of motor neuron disease across ethnicities and geographical areas: focus on Arabic countries in the Mediterranean area Some populations do not fit neatly into either pattern. A study in Cyprus, for example, found a high proportion of familial ALS but could not identify pathogenic variants in any of the common ALS genes, suggesting that undiscovered genes specific to that population may be involved.21Scientific Reports. Genetic epidemiology of amyotrophic lateral sclerosis in Cyprus: a population-based study
These population differences are not just academic curiosities. They affect which genetic tests are most informative for a given patient, which clinical trials they might be eligible for, and what kind of disease course to expect. A gene panel designed primarily around European ALS cohorts may miss important variants in patients from other backgrounds.
The ALS–Frontotemporal Dementia Overlap
ALS and frontotemporal dementia are increasingly understood as two ends of a single neurodegenerative spectrum. The overlap is partly clinical: some people with ALS develop cognitive and behavioral symptoms, and some people with frontotemporal dementia develop motor-neuron problems. But the overlap is also firmly genetic. Several of the same genes, most prominently C9orf72, TARDBP, FUS, and TBK1, can cause either disease or both simultaneously.22PubMed Central. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia For families carrying one of these shared mutations, a relative with frontotemporal dementia counts as part of the family history even if no one has ever had ALS. That matters for genetic counseling, because a family might not recognize the connection and could underreport their risk.
Genetic Testing and Counseling
Genetic testing for ALS is increasingly available, but deciding whether to pursue it, especially for unaffected family members, is genuinely complicated. For someone already diagnosed with ALS, testing can identify a specific mutation that may affect prognosis, inform treatment options, and help relatives understand their own risk. For an at-risk person without symptoms, however, the stakes are different. A positive result means living with the knowledge that you carry a mutation associated with ALS, without knowing whether or when you will develop the disease, since penetrance varies widely across mutations and individuals.
Expert guidelines recommend that presymptomatic genetic testing should generally not be pushed on at-risk relatives unless they seek it out or are enrolled in a research program.23Journal of Neurology, Neurosurgery & Psychiatry. Genetic counselling in ALS: facts, uncertainties and clinical suggestions Counseling needs to be multidisciplinary, addressing uncertainties about penetrance, the possibility that a person may carry variants in more than one relevant gene, and the risk of genetic discrimination in insurance or employment. The psychological, social, and ethical dimensions of ALS genetic testing remain relatively underexplored compared with better-studied conditions like hereditary breast cancer. Specialized centers have developed protocols for this process, drawing on experiences with presymptomatic testing for conditions like Huntington’s disease, but adapting them to the greater genetic complexity of ALS.24PubMed Central. Presymptomatic ALS genetic counseling and testing: Experience and recommendations
Gene-Targeted Therapies Are Arriving
The identification of specific ALS-causing genes has opened the door to treatments aimed at the root cause rather than just managing symptoms. The most advanced example is tofersen, a drug delivered into the spinal fluid that targets the messenger RNA produced by the SOD1 gene, essentially turning down production of the toxic misfolded protein. In clinical trials, tofersen reduced SOD1 protein levels in spinal fluid and lowered blood levels of neurofilament light chain, a marker that tracks with disease progression, by about 60 percent.25PubMed. Tofersen: A Novel Option for the Treatment of Amyotrophic Lateral Sclerosis
The clinical picture was more nuanced. The initial 28-week trial did not show a statistically clear difference in functional decline between tofersen and placebo. But patients who started the drug early fared better over 52 weeks than those who started after a delay, and a systematic review combining multiple studies found that tofersen slowed the rate of functional decline and reduced loss of breathing capacity compared to placebo.26PubMed. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS27PubMed Central. Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis The drug was approved on the strength of its biomarker effects and the suggestion of clinical benefit, though researchers are clear that longer and larger studies are still needed.
Similar approaches are being developed for other ALS genes. Antisense therapies targeting C9orf72, FUS, TARDBP, and ATXN2 are in various stages of clinical testing.28PubMed Central. Antisense Oligonucleotide Therapy for Amyotrophic Lateral Sclerosis (ALS): An Umbrella Review The existence of these gene-specific drugs is a strong argument for genetic testing in diagnosed patients: knowing your mutation could determine whether you are eligible for a treatment that specifically addresses your form of the disease.
Catching ALS Before Symptoms Start
One of the most tantalizing prospects in ALS genetics is the possibility of detecting disease before symptoms appear. In people who carry known ALS mutations and are being monitored, researchers found that blood levels of neurofilament light chain, a protein released when nerve cells are damaged, began rising roughly a year before the first clinical signs of disease appeared.29PubMed Central. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion The levels continued climbing through at least the first six months after symptom onset. In at-risk individuals who remained healthy, levels stayed low and rose only modestly with age.
This kind of presymptomatic detection matters because gene-targeted therapies like tofersen show hints of working better the earlier they are started. If a drug can slow or prevent the cascade of motor-neuron damage before obvious disability sets in, early identification of carriers who are on the cusp of disease becomes critically important. Ongoing studies are now enrolling presymptomatic carriers of SOD1 mutations to test whether starting tofersen before symptoms emerge can delay or prevent disease onset altogether.
Lab Models Built from Patient Cells
One reason ALS genetics has been so hard to untangle is that you cannot easily study living human motor neurons in a dish. That is changing. Researchers have developed three-dimensional organoids, miniature clusters of human nerve and muscle cells grown from stem cells, that replicate key features of ALS, including protein mislocalization, defects at the junction between nerves and muscles, and the contribution of support cells to motor-neuron death.30PubMed Central. Modeling ALS in a dish: how organoids are transforming research When organoids are grown from stem cells taken from ALS patients or engineered to carry familial ALS mutations, they show measurable impairment in the connections between nerve and muscle cells.31Nature Communications. Human sensorimotor organoids derived from healthy and amyotrophic lateral sclerosis stem cells form neuromuscular junctions
These models serve as test platforms for drug screening, and they allow researchers to compare, in the same system, how different ALS mutations produce different downstream effects. For a disease where every identified gene seems to damage motor neurons through a distinct pathway, having a human-tissue-based model for each one is a meaningful advance. It also begins to address a longstanding limitation: most earlier ALS research relied heavily on mice carrying SOD1 mutations, which is only one slice of a genetically diverse disease.